Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease due to deficient alpha-L-iduronidase (IDUA)activity. It results in bone and joint abnormalities, cardiac disease, growth retardation, and corneal clouding, and is usually associated with early death and mental retardation. We have previously demonstrated that neonatal injection of a retroviral vector expressing beta-glucuronidase (GUSB) results in efficient transduction of hepatocytes, which secrete mannose 6-phosphorylated GUSB that can be taken up by other organs. This results in improvement in many of the clinical manifestations of the related disorder, MPS VII, in both mice and dogs. There are two reasons for extending this approach to treat MPS I, which is the goal of this project. First, MPS I dogs usually make potent immune responses to IDUA, which will allow the immunological consequences of this gene therapy approach to be better understood. This will be important """"""""to define prior to using this approach in humans with null mutations"""""""". Second, MPS I is the most common of the MPS syndromes with an incidence of 1:100,000 live births, while MPS VII is quite rare. The higher incidence of MPS I will facilitate identifying patients to treat should this approach prove to be safe and effective. This project will involve development of a retroviral vector expressing the canine IDUA cDNA. Initial studies will deliver the vector to hepatocytes of newborn mice or dogs with MPS I. Animals will be evaluated for enzyme levels in organs and blood, immunological responses to clDUA, and clinical and pathological manifestations of lysosomal storage disease. Although treatment of newborns has many advantages and may reduce immunological responses, most patients with MPS I are diagnosed well after birth. We will therefore test if this retroviral vector can be delivered to juvenile animals with MPS I, and if this is more likely to generate an immune response. If immune responses develop, immune modulators will be given at the time of gene therapy to prevent their development. Finally, one of the devastating features of severe MPS is mental retardation, and this liver-directed approach may be ineffective at treating this aspect of disease. We will therefore test if modification of the IDUA protein produced by the liver can improve delivery to the brain from the blood. This project may result in application of this approach for patients with MPS I in the future, although clinical trials are not proposed here.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK066448-05
Application #
7099630
Study Section
Special Emphasis Panel (ZRG1-GTIE (91))
Program Officer
Mckeon, Catherine T
Project Start
2003-10-03
Project End
2007-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
5
Fiscal Year
2006
Total Cost
$286,480
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Provenzale, James M; Nestrasil, Igor; Chen, Steven et al. (2015) Diffusion tensor imaging and myelin composition analysis reveal abnormal myelination in corpus callosum of canine mucopolysaccharidosis I. Exp Neurol 273:1-10
Xing, Elizabeth M; Wu, Susan; Ponder, Katherine P (2015) The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice. Mol Genet Metab 114:209-16
Chiaro, Joseph A; O'Donnell, Patricia; Shore, Eileen M et al. (2014) Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs. J Bone Miner Res 29:2610-7
Chiaro, Joseph A; Baron, Matthew D; Del Alcazar, Chelsea M et al. (2013) Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs. Bone 55:78-83
Baldo, Guilherme; Wozniak, David F; Ohlemiller, Kevin K et al. (2013) Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits. J Inherit Metab Dis 36:499-512
Baldo, Guilherme; Mayer, Fabiana Quoos; Martinelli, Barbara et al. (2012) Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice. Behav Brain Res 233:169-75
Dickson, Patricia I; Ellinwood, N Matthew; Brown, Jillian R et al. (2012) Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. Mol Genet Metab 106:68-72
Lyons, Jeremiah A; Dickson, Patricia I; Wall, Jonathan S et al. (2011) Arterial pathology in canine mucopolysaccharidosis-I and response to therapy. Lab Invest 91:665-74
Dierenfeld, Ashley D; McEntee, Michael F; Vogler, Carole A et al. (2010) Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2:60ra89
Visigalli, Ilaria; Delai, Stefania; Politi, Letterio S et al. (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116:5130-9

Showing the most recent 10 out of 19 publications